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a b s t r a c t
In recent years, microRNA-targeting has become an effective strategy for selective control of tissue-
tropism and pathogenesis of both DNA and RNA viruses. Here, using a neurotropic ﬂavivirus as a model,
we demonstrate that simultaneous miRNA targeting of the viral genome in the open reading frame and
30-noncoding regions for brain-expressed miRNAs had an additive effect and produced a more potent
attenuation of the virus compared to separate targeting of those regions. Multiple miRNA co-targeting of
these two distantly located regions completely abolished the virus neurotropism as no viral replication
was detected in the developing brain of neonatal mice. Furthermore, no viral antigens were detected in
neurons, and neuronal integrity in the brain of mice was well preserved. This miRNA co-targeting
approach can be adapted for other viruses in order to minimize their replication in a cell- or tissue-type
speciﬁc manner, but most importantly, to prevent virus escape from miRNA-mediated silencing.
Published by Elsevier Inc.
Introduction
The mosquito- and tick-borne viruses of the Flaviviridae family
represent important emerging and reemerging pathogens such as
Japanese encephalitis, St. Louis encephalitis, West Nile, and tick-
borne encephalitis (TBEV) viruses that have caused severe neu-
roinfections with up to 40% mortality in humans in many regions
of the world (Lindenbach et al., 2007; Sips et al., 2012). The
pathogenesis of neurotropic ﬂavivirus infections involves two
distinct properties of the viruses: (i) neuroinvasiveness, which
relates to the capacity of the virus to replicate in the peripheral
organs, induce viremia, and gain entry to the central nervous
system (CNS) and (ii) neurovirulence, which is the ability of the
virus to infect and replicate in cells of the CNS and cause
encephalitis (Mandl, 2005). In the CNS, the primary targets of
neurotropic ﬂaviviruses are neurons (Grifﬁn, 2003). Successful
attenuation of a neurotropic virus depends on the prevention of
virus entry into the CNS and restriction of its replication in the
neurons. In recent years, microRNAs (miRNAs) have emerged as
important cellular RNA elements that regulate gene expression at
the posttranscriptional level by targeting mRNAs for translational
repression or enzymatic degradation. As many cellular miRNAs
have a distinctive cell type-speciﬁc pattern of expression (Bartel,
2009; Filipowicz et al., 2008; Lagos-Quintana et al., 2002). miRNA
targeting of viral genomes has been exploited to restrict virus
replication and pathogenesis in a cell- or tissue-speciﬁc manner
(Kelly and Russell, 2009; tenOever, 2013). Initially tested for
picornaviruses (Barnes et al., 2008; Kelly et al., 2008), cell-
speciﬁc miRNA-dependent suppression of virus replication has
proved to be effective in vivo for both DNA and RNA viruses
(Cawood et al., 2009, 2011; Edge et al., 2008; Kelly et al., 2010a,b;
Langlois et al., 2013; Leber et al., 2011; Perez et al., 2009; tenOever,
2013; Ylosmaki et al., 2008, 2013).
Despite the success in controlling viral tissue-tropism and
pathogenesis by cellular miRNAs, a major concern for this
approach is associated with virus escape from miRNA-mediated
inhibition and potential reversion to a virulent phenotype (Barnes
et al., 2008; Kelly et al., 2008; tenOever, 2013). We have previously
demonstrated that certain miRNAs expressed in the brain can
control the neurotropism of a ﬂavivirus bearing perfectly comple-
mentary miRNA target sites (Heiss et al., 2011, 2012). Insertion of a
single copy of a target for a mir-9, mir-124a, mir-128a, mir-218, or
let-7c miRNA into the 30 noncoding region (30NCR) of neurotropic
chimeric TBEV/Dengue type 4 virus (TBEV/DEN4) was sufﬁcient to
block virus replication in the CNS of adult mice and prevent the
development of otherwise lethal encephalitis (Heiss et al., 2011).
However, the effect of these miRNA target insertions on viral
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neurovirulence in newborn mice was less evident, as emerging
mutations or deletions within the miRNA target sequences of escape
mutants restored the ability of the virus to replicate in the CNS and to
cause fatal disease (Heiss et al., 2012). Incorporation of multiple
copies of miRNA targets in the 30NCR and extension of the distance
between these targets led to a more effective miRNA-mediated
suppression of virus replication. Importantly, the attenuated pheno-
type was seen even in the developing CNS of suckling mice and in
immuno deﬁcient SCID mice that lack potent B and T cell responses
(Heiss et al., 2012). However, occasional large deletions of miRNA
targets as well as viral genome sequences located between them
restored the neurovirulent phenotype in these animal models. These
ﬁndings prompted us to test whether simultaneous placement of
multiple miRNA target sequences at different functionally important
regions of the viral genome would greatly reduce or completely
prevent virus escape from miRNA-mediated selective suppression. In
the present study, we ﬁrst explored the effect of miRNA targeting in
the open reading frame (ORF) of the viral genome, within the region
encoding the C-terminal part of the E protein. We next investigated
the effects of simultaneous miRNA co-targeting in two distant
regions of the viral genome, i.e., in the ORF and 30NCR. We
show here that such combined targeting of the viral genome had
an additive effect on reducing neurovirulence of a virus and resulted
in no death or neurological signs in newborn mice. No viral
replication, neuro degeneration, or virus escape was detected in
mouse brains.
Results
Construction of TBEV/DEN4 viruses bearing miRNA targets in the ORF
of viral genome
In this study, we explored the ability of cellular miRNAs
abundantly expressed in the brain to selectively restrict replication
of neurotropic ﬂaviviruses in the CNS by insertion of miRNA
Fig. 1. Schematic representation of viral genomes used in this study. (A) Parental TBEV/DEN4 chimeric virus (Pletnev et al., 1992). Gray area represents TBEV sequences;
white area depicts DEN4 virus sequences. Insert shows the junction between the TBEV and DEN4 sequences in the C-terminal end of protein E coding sequence with
transmembrane helices TM1 and TM2. Black arrow indicates signalase cleavage site between proteins E and NS1. (B) Schematic illustration of the insertion of target
sequences for miRNAs in the area coding for the C-terminal end of protein E. Dashed lines mark sequences inserted at the Xho I site of the parental genome; black arrows
indicate duplicated signalase cleavage site; dotted area between TBEV and DEN4 sequences represents inserted miRNA target sequences. (C) Schematic diagram of viruses
with combined target sequences in the ORF and 30NCR. Positions of 3 mir124a target sequences in the 30NCR are schematically depicted by white boxes.
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targets in a region of the viral genome inside of the ORF, in the
sequence located between TBEV E and DEN4 NS1 protein genes of
the chimeric TBEV/DEN4 virus (Pletnev et al., 1992). This chimeric
virus contains sequences encoding the structural prM and E
proteins of the Far Eastern TBEV with remaining genes derived
from mosquito-borne DEN4 virus (Fig. 1). The junction between
TBEV and DEN4 sequences at the C-terminal anchor region of
protein E was placed so that the ﬁrst transmembrane helix (TM1)
of protein E had the TBEV sequence, while the second transmem-
brane helix (TM2) contained the DEN4 sequence (Fig. 1A). We
designed the insertion of miRNA target sequences in this region
using an approach that has been described previously by Bonaldo
et al. (2007) for generation of recombinant yellow fever viruses
expressing foreign genes (Trindade et al., 2012). The C-terminal
stem-anchor (SA) region of protein E (100 amino acid residues)
contains four alpha-helices, two of which (H1 and H2) form a stem
region, and two amphipathic anti-parallel α-helices (TM1 and
TM2) serve as an E protein membrane anchor and as an internal
signal sequence for the cellular signal peptidase cleavage during
polyprotein processing (Fritz et al., 2011; Pangerl et al., 2011;
Stiasny et al., 2013). Three tandem target sequences for miRNAs
were placed between sequences encoding the two SA domains:
the ﬁrst SA domain, located upstream of the miRNA-targets, was a
part of the TBEV E protein; the second SA domain, located down-
stream of the miRNA targets, contained the sequence from the
DEN4 E protein (Fig. 1B). Complementary targets for mir-9 and
mir-124a miRNAs were selected for insertion into the TBEV/DEN4
genome, since these miRNAs are highly expressed in mouse brains,
and insertion of these targets into the chimeric TBEV/DEN4
genome effectively restricted virus replication in neurons and
prevented the development of otherwise lethal encephalitis in
mice inoculated into the brain (Heiss et al., 2011, 2012). Two
variants of miRNA-targeted TBEV/DEN4 viruses were engineered
by insertion of the designed synthetic sequences (Fig. S1) into the
unique Xho I site of the TBEV/DEN4 cDNA genome (Fig. 1B). The
vE1 cDNA carried two targets for mir-124a and one target for mir-
9 between them, whereas vE2 cDNA carried three tandem copies
of targets for mir-124a. As a control, we generated a third variant
vE3 virus, in which miRNA targets of vE1 were modiﬁed in each
third nucleotide position presumably preventing recognition of
these sequences by cellular miRNAs (Fig. S1).
To target viral genomes in two distantly located regions, we
also engineered TBEV/DEN4 cDNA genomes in which the above
insertions in vE1, vE2, or vE3 were combined with three additional
mir-124a targets located in the 30NCR of the viral genome. We
selected and utilized two previously described variants of miRNA-
targeting in the 30NCR of TBEV/DEN4: 3xmir124aT(1,2,4) [desig-
nated here as vA3] and 3xmir124aT(1,2,5) [designated here as
vA5] that carry three mir-124a binding sites in the 30NCR at
positions 1, 2, and 4 or 1, 2 and 5 (Heiss et al., 2012). Six viruses
(designated vE1/A3, vE1/A5, vE2/A3, vE2/A5, vE3/A3, and vE3/A5)
were generated from the engineered cDNA genomes as shown
in Fig. 1C.
Simian Vero or mosquito C6/36 cells, neither of which
expresses the mir-9 or mir-124a miRNAs as measured by TaqMan
microRNA assay (Heiss et al., 2011), were able to support the
recovery of modiﬁed TBEV/DEN4 viruses after transfection with
RNAs transcribed from the cDNAs. Viruses were ampliﬁed by one
additional passage and biologically cloned by two subsequent
terminal dilutions. Cloned viruses were ampliﬁed in Vero cells
by two or three additional passages and reached a titer of at least
108 PFU/ml. Genetic stability of the insertions in the genomes of
the produced recombinant viruses was evaluated by additional
multiple passages in Vero cells at low multiplicity of infection
(0.01 PFU/cell). All viruses were genetically stable and contained
the designed insertions as veriﬁed by sequence analysis of viral
RNA genomes determined after 6, 8, and 10 passages in Vero cells.
Expression of viral proteins in Vero cells
To determine if viral polyproteins were proteolytically pro-
cessed correctly in cells infected with vE1, vE2 and vE3 viruses
bearing insertions in the ORF, we examined viral protein expres-
sion in infected cells by Western blot analysis. Vero cells were
infected with each modiﬁed or parental virus at an MOI of 0.5, and
cell lysates and supernatants were analyzed on day 3 p.i. The
immunoblot patterns revealed that TBEV E protein and DEN4 NS1
and NS3 proteins of the TBEV/DEN4 parental virus and vE1, vE2,
and vE3 derivative viruses co-migrated by SDS–PAGE (Fig. 2A),
indicating correct processing of polyprotein. The expected poly-
peptide band corresponding to the product encoded by insertion
in vE1, vE2, or vE3 and containing the DEN4 SA region of
the E protein was not detected by TBEV- or DEN4-speciﬁc
antibodies. To verify the expression of this new polypeptide, we
added the sequence encoding the commonly used FLAG-tag
epitope upstream of the miRNA target sequences in each of the
three recombinant viruses, generating vE1-FLAG, vE2-FLAG, and
Fig. 2. Immunoblot analysis of viral proteins expressed in Vero cells. (A) Vero cells
were infected with TBEV/DEN4, vE1, vE2 or vE3 viruses as speciﬁed at the top. After
72 h p.i., cell culture supernatants were collected (sup) and cells were harvested
and processed to prepare cell lysates (lys). The samples were analyzed by
immunoblotting using antibodies indicated on the right. The positions of molecular
weight (MW, in kDa) markers are indicated on the left. (B) Vero cells were infected
with TBEV/DEN4, vE2 and vE2-FLAG or mock-infected. After 72 h cells were
harvested and cell lysates were processed as described for panel A. The samples
were analyzed by immunoblotting using the antibodies indicated on the left.
Positions of E, NS3, NS1 proteins and FLAG-tagged C-terminal E protein peptide
encoded by insertion (FLAG-Epep) are indicated by arrows on the right side of each
panel. * indicates positions of unspeciﬁc protein bands recognized by TBEV or DEN4
HAMF in mock-infected cells.
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vE3-FLAG viruses. As shown in Fig. 2B, the expected polypeptide of
14 kDa was detected and speciﬁcally recognized by the mouse
monoclonal anti-FLAG antibodies in the lysates of cells infected
with vE2-FLAG. Similar bands were observed for cells infected
withvE1-FLAG and vE3-FLAG (data not shown). The anti-FLAG
antibodies did not detect any additional bands of higher molecular
weight corresponding to potential intermediate products contain-
ing a cleavage site for the cellular signalase. These results suggest a
complete and correct processing of the viral E and NS1 proteins
from the polyprotein precursor.
Replication of miRNA-targeted viruses in primary neuronal cells
To evaluate miRNA-mediated restriction of virus replication
in vitro, growth of parental TBEV/DEN4 and engineered viruses
was monitored in primary neuronal cells derived from the
embryonic rat cortex which express high levels of mir-9 and
mir-124a miRNAs (Krichevsky et al., 2003). Parental TBEV/DEN4
virus and the vE3 derivative with the scrambled miRNA target
sequences replicated efﬁciently in these cells, reaching virus titers
of 7.0 and 6.1 log10 PFU/ml, respectively, by day 3 p.i. Insertion of
three copies of the mir-124a targets in the ORF of the vE2 virus
signiﬁcantly impaired virus replication in neuronal cells, as the
yield of vE2 virus was reduced by 1000- or 100-fold compared to
that of parental virus or control vE3 virus, respectively (Fig. 3A).
Immunostaining of TBEV antigens in the infected cells demon-
strated that replication of the vE2 virus was signiﬁcantly restricted
in the majority of cells (Fig. 3B). Surprisingly, targeting of the viral
genome in the same site for two different miRNAs (mir-9 and mir-
124a) did not produce such restriction of virus replication. The
levels of replication for both vE1 mutant and control vE3 virus
were similar indicating that such combination of miRNA targets
(mir-124aT-9T-124aT) placed within the ORF of the viral genome
was not effective for viral attenuation in vitro. Sequence analysis of
the viral RNAs isolated from the supernatants of neuronal cells at
72 h post-infection demonstrated the presence of input viruses
(vE1 or vE2) together with their corresponding escape deletion
mutants that lost all inserted miRNA target sequences. However,
the genome of the control virus E3 remained stable during
replication in neuronal cells (data not shown).
When three miRNA target sequences in the ORF were com-
bined with three additional mir-124a targets in the 30NCR, an
additive effect on the restriction of virus replication in neuronal
cells was manifested. Replication of the viruses vE2/A3 and vE2/A5,
with 6 copies of mir124aT, was decreased a further50- and100-fold
compared to that of viruses carrying 3 copies of target sequences
either in the ORF (vE2 virus; Fig. 3A) or the 30NCR (vE3/A3 and vE3/A5;
Fig. 3C) alone.
Neurovirulence of viruses with miRNA targets inserted in the ORF
The neurovirulence of the recombinant viruses was evaluated
in suckling mice, a most sensitive animal model for assessment of
ﬂavivirus neurovirulence. As shown in Table 1, targeting the viral
genome inside of the ORF with three copies of target sequence for
the brain-expressed mir-124a resulted in substantial attenuation
of vE2 in newborn mice. Of 30 mice that received an intra cerebral
dose of 10, 100, or 1000 PFU, only three mice developed neurolo-
gical signs (limb weakness or paralysis), while the rest of the mice
remained asymptomatic during the 21 day observation period. The
IC LD50 of vE2 virus was greater than 1000 PFU and increased over
1250-fold compared to parental TBEV/DEN4 virus [IC LD50 of
0.8 PFU (Heiss et al., 2012)]. The neurovirulence of the control
vE3 virus carrying scrambled miRNA targets remained high (LD50
of 23.7 PFU), indicating that the attenuation phenotype of vE2 is
speciﬁc and determined by the presence of three mir-124a target
sequences. At the same time, substitution of one mir-124a target
sequence in the vE2 with the target sequence for another brain-
expressed miRNA (mir-9) signiﬁcantly decreased the attenuation
effect, as observed for vE1 (an estimated IC LD50for vE1 was
44.7 PFU).
Fig. 3. Effect of miRNA target insertions on TBEV/DEN4 virus replication in primary neuronal cells. (A and C) Neuronal cells were infected at MOI of 0.5 with the indicated
viruses, and culture mediumwas collected at 72 h p.i. Virus titers in culture mediumwere determined by PFA on Vero cells. Values for each virus, determined in triplicates in
the same experiment, are shownwith corresponding standard deviations. (B) TBEV antigen (TBEV-Ag) expression in primary neuronal cells detected by immunoﬂuorescence
assay with αTBEV HMAF four days after infection with the indicated viruses or mock inoculated. TBEV-Ag – green, DAPI – blue.
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Combined miRNA-targeting in the ORF and 30NCR had an
additive effect and resulted in a more profound reduction of
neurovirulence of TBEV/DEN4 virus in newborn mice. No death
or neurological signs were observed in mice inoculated into the
brain with 10, 100, or 1000 PFU of vE1/A3, vE1/A5, vE2/A3, or
vE2/A5. Also, two viruses (vE3/A3 and vE3/A5) with 3 copies of
mir-124a target sequences in the 30NCR and scrambled miRNA
targets in the ORF exhibited substantial attenuation in newborn
mice, similar to that observed for viruses (vA3 and vA5) with the
same combination of target sequences in the 30NCR alone (Heiss
et al., 2012). Only 1 or 2 of 30 mice infected with vE3/A3 or vE3/A5
viruses, respectively, developed paralysis after a longer incubation
period compared to that of mice infected with the TBEV/DEN4
parent (Table 1).
On day 22, the brains of ﬁve surviving mice were collected from
each group (groups 4-3, 5-3, 6-3, 7-3, 8-2, and 9-3; Table 1) that
was infected with the highest dose. Each individual brain suspen-
sion was tested in Vero cells for the presence of infectious virus.
Infectious virus was isolated only from the brain of one of ﬁve
animals injected with vE3/A5 virus. Sequence analysis of this
isolate identiﬁed alarge deletion (339 nts) in the 30NCR that began
close to the TAA stop codon of the ORF and included the
introduced three mir-124a targets and genome sequence located
between them. The brains from all other animals were free
from inoculated virus as determined by plaque assay or RT-PCR
analysis, and no virus was isolated after additional blind passage
on Vero cells.
These results indicate that simultaneous multiple miRNA tar-
geting of the viral genome within the ORF and 30NCR produces a
strong attenuating effect on virus neurovirulence and is sufﬁcient
to prevent virus escape from miRNA-mediated suppression in
the brain.
Genetic stability of miRNA-targeted viruses in the CNS
Virus escape from miRNA pressure in the CNS by accumulation
of mutations or deletions within the miRNA targets is a common
occurrence among viruses carrying target sequences in the 30NCR
(Barnes et al., 2008; Heiss et al., 2011, 2012; Lauring et al., 2010;
Ylosmaki et al., 2013). Here, we examined whether the onset of
viral encephalitis observed in suckling mice inoculated with
viruses bearing miRNA targets in the ORF was the result of a
similar process. We sequenced the region encoding the C-prM-E-
NS1 proteins of 19 viruses isolated from brains of individual mice
that succumbed to the IC infection (Table 1). The sequence analysis
results are shown in Fig. S2 in the supplemental material.
Sequences of viral RNAs derived from the brains of four moribund
mice infected with the control vE3 virus, were identical to the
sequence of the input virus, indicating that the inserted sequences
of the scrambled miRNA targets were stable during virus
Table 1
Neurovirulence of chimeric TBEV/DEN4 miRNA-targeted viruses in suckling mice.
Virus Groupa Dose
(PFU)
No. of moribund
mice on the
indicated day
(dpi)b
Morbidity
(%)
LD50
(PFU)
Fold
reductionc
vE1 1–1 10 2(d14) 20 44.7 56
1–2 102 3(d10), 3(d11),
2(d13)
70
1–3 103 5(d10), 4(d11) 90
vE2 2–1 10 0 41000 41250
2–2 102 1(d14) 10
2–3 103 1(d15), 1(d18) 20
vE3 3–1 1 0 23.7 30
3–2 10 1(d10), 1(d15) 20
3–3 102 10(d10) 100
vE1/A3 4–1 10 0 41000 41250
4–2 102 0
4–3 103 0
vE1/A5 5–1 10 0 41000 41250
5–2 102 0
5–3 103 0
vE2/A3 6–1 10 0 41000 41250
6–2 102 0
6–3 103 0
vE2/A5 7–1 10 0 41000 41250
7–2 102 0
7–3 103 0
vE3/A3 8–1 10 0 4100 4125
8–2 102 1(d15) 10
vE3/A5 9–1 10 0 41000 41250
9–2 102 1(d14), 1(d17) 20
9–3 103 0
TBEV/
DEN4
10 10 6(d8), 4(d9) 100 0.8d
a Groups of 10 3-day-old Swiss mice were inoculated IC with the indicated dose of virus.
b The brains of paralyzed mice were collected on the indicated day, and viral RNA was isolated from brain homogenate and directly used for sequence analysis. The
results of sequence analysis of brain-derived escape mutant viruses are shown in Fig. S2 in the supplemental material.
c Fold reduction in neurovirulence for each miRNA-targeted virus compared to that of the TBEV/DEN4 parent.
d The IC LD50 of TBEV/DEN4 from the previous studies (Engel et al., 2010; Heiss et al., 2012).
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replication in the mouse brain. Also, in six of the 13 brain-derived
vE1 isolates, no mutations or deletions were detected. However,
seven vE1 isolates as well as two vE2 brain-derived viruses
contained large deletions (from 81 to 603 nts). The observed
deletions can be divided in two groups. In the ﬁrst group,
relatively short deletions were found in vE2-Δ81, vE1-Δ147, vE1-
Δ165, vE1-Δ219, and vE1-Δ270 escape mutants that partially
eliminated sequences located between the two encoded sites for
signalase cleavage and including the miRNA targets (Figs. 4 and S2).
With the exception of the vE1-Δ219 virus, all these escape mutants
were infectious for Vero cells and replicated to titers of at least
106 PFU/ml when ampliﬁed in cells at 37 1C. The second group of
brain-derived viruses (vE2-Δ447, vE1-Δ402, and vE1-Δ411; Fig. 4)
acquired larger deletions, which included stem-anchor structural
elements of the TBEV E protein and the E/NS1 signalase cleavage site
(Fig. S2). These viruses contained chimeric E proteins with the H1
sequence of TBEV, TM1 and TM2 sequences from DEN4, and a newly
formed H2 stem helix. Joining of TBEV and DEN4 H2 remnants
resulted in the variable size of this element (e.g., an increase in theH2
size by 7 amino acids in vE1-Δ411 or a decrease by 4 amino acids in
vE2-Δ447).
Multiple site miRNA co-targeting within the ORF and 30NCR greatly
restricts virus replication and prevents neuronal degeneration in the
CNS
Previous studies had demonstrated that increasing the number
of mir-124a targets to four copies in the 30NCR signiﬁcantly
diminished virus replication (Heiss et al., 2012). In the current
study, we explored whether the insertion of 6 miRNA binding sites
in two regions (ORF and 30NCR) of the viral genome would further
reduce virus replication in the brain and minimize virus-induced
neuronal damage.
Three-day old mice were inoculated IC with 103 PFU of each of
the following viruses: vE1/A3, vE1/A5, vE2/A3, vE2/A5, vE3/A3, or
vE3/A5. The brains of three mice from each group were collected
on days 8, 13, and 20, and virus loads in each individual brain were
determined by titration on Vero cells. We have previously shown that
the TBEV/DEN4 virus rapidly achieved high titers (10.2 log10 PFU/g of
brain) and caused paralysis or death by day 7 p.i. when inoculated IC
at this high dose (Engel et al., 2010; Heiss et al., 2012). Replication of
the viruses with multiple complementary miRNA targets within the
ORF and 30NCR (i.e., vE1/A3, vE1/A5, vE2/A3, and vE2/A5 viruses) was
below the level of detection (o1.7 log10 PFU/g) and all mice remained
healthy (Fig. 5). At the same time, viruses with scrambled miRNA
target sequences in the ORF (i.e., vE3/A3 and vE3/A5) were able to
replicate, albeit to low levels (up to 2.7 log10 PFU/g) and without
producing any clinical signs (Fig. 5).
Fig. 4. Location and size of the deletions in the ORF of escape mutants detected in the brains of moribund mice infected IC with miRNA-targeted viruses. Schematic diagram
of the insertion of target sequences for miRNAs in the area encoding the C-terminal end of protein E. Dotted lines mark sequences inserted at the Xho I site of the parental
genome; black arrows indicate duplicated signalase cleavage sites; dotted area between TBEV sequences (shown in gray) and DEN4 sequences (illustrated in white)
represents inserted miRNA target sequences. The size of the deletions detected in the isolated escape mutants (number of nucleotides deleted) is shown in the right column
and their locations in the ORF are indicated by double head arrows. Amino acid sequences for each deletion mutant are shown in Fig. S2 in the supplemental material.
Fig. 5. Replication kinetics of recombinant TBEV/DEN4 viruses with miRNA target
sequences within the ORF and 30NCR in mouse brain. 3-day-old Swiss mice were
inoculated IC with 1000 PFU of the indicated viruses. Brains were collected from
three mice in each group on day 8, 13 and 20, and virus titers were determined by
PFA on Vero cells. The limit of detection (1.7 log10 PFU/g of brain) is indicated by the
dashed line.
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We next analyzed the distribution of viral antigens and virus-
induced histopathology in the brains of infected mice. Simulta-
neous immunostaining of multiple mouse brains (MultiBrain
Technology, NeuroScience Associates) for the TBEV viral antigens
corroborated the data on virus replication (Fig. 6). Various neuro-
nal populations throughout the brain of mice infected with the
parental TBEV/DEN4 virus displayed massive amounts of viral
antigens (Fig. 6C–I). In line with the low levels of detected
infectious virus, viral antigens of the vE3/A3 and vE3/A5 virus
were detected only in very small amounts in some cortical
neurons and Purkinje cells (Fig. 6J and L; vE3/A5 virus is shown).
No viral antigens were detected in neurons of mice inoculated
with the vE1/A3, vE1/A5, vE2/A3, or vE2/A5 virus at any time point
(Fig. 6A and B; vE2/A3 is shown).
The extent of histopathological changes also correlated well
with the virus titers and amounts of viral antigens observed. The
parental TBEV/DEN4 virus induced extensive damage to neuronal
somatodendritic compartments and microgliosis (Fig. 7B). In mice
inoculated with the vE1/A3, vE1/A5, vE2/A3, or vE2/A5 virus, the
integrity of neuronal somatodendritic compartments was well
preserved and microglia maintained its “quiescent/surveying”
phenotype (compare Fig. 7C, E2/A3 virus, and Fig. 7A, Mock). The
brains of mice inoculated with the vE3/A3 or vE3/A5 virus also did
not show signs of neuronal damage, but microglia appeared acti-
vated, albeit to a much lesser extent than in the TBEV/DEN4-infected
mice (Fig. 7C, vE3/A5 virus is shown). Since microglia are very
sensitive to even minor insults, the microglial morphology seen in
mice infected with the vE3/A3 or vE3/A5 virus is indicative of
ongoing low-level virus replication of these viruses.
Taken together, these ﬁndings clearly demonstrate that multi-
ple miRNA co-targeting in the ORF and 30NCR leads to inability of
the targeted virus to establish a productive neuroinfection.
Multiple miRNA target insertions within the ORF and 30NCR do not
disrupt virus immunogenicity and protective efﬁcacy
To determine the ability of the TBEV/DEN4 viruses with a
combination of six miRNA targets in ORF and 30NCR to replicate in
the periphery and induce protective immunity, adult immuno-
competent Swiss female mice in groups of 10 were inoculated IP
with a 105 PFU dose of parental TBEV/DEN4 or miRNA-targeted
virus. All mice remained healthy during the 28-day observation
period and developed a moderate level of TBEV-speciﬁc neutraliz-
ing antibodies in serum (from 1:10 to 1:26 as determined by
plaque reduction neutralization assay 60%). On day 29, mice were
challenged with 100 IP LD50 of the neuroinvasive TBEV/LGT virus
(IP LD50 of 32 PFU was determined in 3-week-old mice) and
observed for an additional 28 days for morbidity and mortality.
All mice immunized with vE1/A3, vE1/A5, vE2/A3, vE2/A5, or
Fig. 6. Distribution of viral antigens in neurons of infected mice. Immunohistochemical detection of the TBEV antigens is shown in representative brain sections from a
mouse IC inoculated with the vE2/A3 virus (A and B; 20 dpi), parental TBEV/DEN4 virus (C–I; 6 dpi), or the vE3/A5 virus (J–N; 20 dpi). Boxed areas in (C) and (D) are shown at
higher magniﬁcation in (E) (cerebral cortex), (F) (hippocampus), (G) (cerebellar cortex), (H) (medial vestibular nucleus), and (I) (reticular nucleus). (J–N) The same brain areas
are shown at high magniﬁcation for a mouse inoculated with E3/A5 virus. Abbreviations: DG, dentate gyrus; CA1 and CA3, areas of hippocampus; M, molecular layer; P,
Purkinje cell layer; G, granule cell layer. Bar in (A) (1 mm) also applies to (B)–(D). Bars in (E)–(N): 100 mm.
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parental TBEV/DEN4 virus survived. To determine whether there
was an age-related resistance of mice to the TBEV/LGT challenge, a
mock-inoculated group of the same age mice as those immunized
served as controls. Eight of ten mice from the control group died
and two mice developed clinical signs of morbidity (ruffed fur,
hunched back and slow movement) during the 28-day observation
after challenge. Thus, mice immunized with a single dose of
TBEV/DEN4 parent or any of its multiple miRNA-targeted viruses
were completely protected against challenge with neuroinvasive
TBEV/LGT virus.
Discussion
MicroRNA targeting provides an effective method to restrict
virus replication in a tissue-speciﬁc manner, and the concept of
miRNA-mediated control of virus tissue-tropism and pathogenesis
has been successfully demonstrated for various viruses that
replicate in peripheral organs (Edge et al., 2008; Kelly et al.,
2008, 2010b; Kelly and Russell, 2009; Langlois et al., 2013; Leber
et al., 2011; Perez et al., 2009; Pham et al., 2012; tenOever, 2013;
Ylosmaki et al., 2008). Silencing of miRNA-targeted viruses might
be a result of both delay of virus replication caused by the miRNA-
speciﬁc suppression, and rapid virus clearance by host immune
responses. In many instances, the selective pressure of cellular
miRNAs on the virus replication was strong and effective, and the
emergence of escape mutant viruses was not observed (Edge et al.,
2008; Kelly et al., 2010b; Langlois et al., 2012, 2013; Perez et al.,
2009). However, the possibility of virus escape by accrual of
mutations in the miRNA-target sequence and reversion to a
virulent phenotype raised a concern about this approach, particu-
larly when it is applied to control neurotropic virus infection in the
CNS (Barnes et al., 2008; Heiss et al., 2011, 2012; Yen et al., 2013;
Ylosmaki et al., 2013). The normal CNS is structurally isolated from
Fig. 7. Extent of neuronal damage and microgliosis in the mouse brain. Immunostaining for the microtubule-associated protein 2 (MAP2) reveals the somatodendritic
neuronal compartments. Immunostaining for the ionized calcium binding adapter molecule 1 (Iba1) reveals microglial morphology. Representative sections of the cerebral
cortex and hippocampus are shown from a mock-inoculated mouse (A; 20 dpi) or mice infected with the TBEV/DEN4 (B; 6 dpi), vE2/A3 virus (C; 20 dpi), or vE3/A5 (D;
20 dpi) virus. Boxed areas of the MAP2-IR are shown at higher magniﬁcation in the corresponding insets on the right. Representative areas of the Iba1-IR are also included in
each panel. Dentate gyrus (DG) and CA3 area of hippocampus are also indicated. Bars: 100 mm.
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the immune system and protected by the blood–brain and blood–
cerebrospinal barriers that limit, but do not exempt the CNS from
immunological surveillance (Mrass and Weninger, 2006; Ousman
and Kubes, 2012). A variety of factors, including the immune
system maturity and levels of miRNA expression and distribution
in the CNS, may play a role in the control of miRNA-targeted virus
replication in the host. Our previous ﬁndings demonstrated that
viral replication and neuronal damage induced by a neurotropic
ﬂavivirus, chimeric TBEV/DEN4 virus, can be selectively attenuated
for the CNS of mice by inserting target sequences for neuron-
speciﬁc miRNAs in the 30NCR of the viral genome (Heiss et al.,
2011, 2012). The degree of virus attenuation for the CNS can be
proportionally enhanced by increasing the number of miRNA
target sites and targeting a large portion of the 30NCR. This
strategy improved the effectiveness of virus suppression by
delaying its replication in the developing CNS of newborn mice,
thus providing a prolonged time for virus clearance by the
immune system. However, miRNA-targeted TBEV/DEN4 viruses
occasionally overcame the antiviral activity of miRNAs and
escaped from miRNA-mediated suppression by deletion of the
inserted miRNA targets and the viral sequences located between
them. This ﬁnding prompted us to place multiple miRNA target
sequences into different functionally important regions of the
virus genome to test whether such targeting would prevent virus
escape. Suppression by targeting in the 50NCR and ORF appears to
be less frequent than 30NCR targeting and generally less effective,
possibly due to ribosome interference with the RNA-induced
silencing complex (RISC) at the translated mRNA sequence
(Bartel, 2009; Filipowicz et al., 2008). However, recent studies on
miRNA regulation of mRNA translation have demonstrated that
miRNA suppression in the coding region can be functional (Fang
and Rajewsky, 2011). In the present study, we ﬁrst evaluated the
placement of target sequences for brain-expressed miRNAs in the
coding region of the TBEV/DEN4 genome between the genes
encoding the E and NS1 proteins and then studied the effect of
simultaneous co-targeting of the viral genome within the ORF and
30NCR. We found that such modiﬁcations of the viral genome do
not affect normal polyprotein processing and the viruses (vE1, vE2
and control vE3) were stable during multiple passages in Vero
cells. In addition, analyses of viruses derived from the brains of
moribund mice inoculated with the control virus vE3 containing
scrambled miRNA target sequences demonstrated that such inser-
tions in the ORF are stable during virus replication in vivo.
Targeting in the ORF with three tandem copies for brain-
expressed mir-124a (vE2) was most efﬁcacious for attenuation of
virus replication in primary neuronal cells and neurovirulence in
neonatal mice. However, the substitution of one copy of mir-124a
target by the target for another brain-expressed miRNA (mir-9) in
vE1 virus considerably decreased the observed attenuation effect
both in vitro and in vivo. This was rather surprising, as in previous
studies we have shown that tandem insertion of mir-9 and mir-
124a target sequences in the 30NCR produced a greater attenuating
effect than tandem insertion of three synonymous mir-124a target
sequences (Heiss et al., 2012). Many factors could contribute to the
effectiveness of miRNA-mediated mRNA translational suppression
when the target sites are relocated into different regions of the
genome or mRNA (Bartel, 2009; Fang and Rajewsky, 2011; Lin and
Ganem, 2011; Pasquinelli, 2012). miRNA-target sequence accessi-
bility for RISC binding, distances between miRNA targets, and
interactions between RISCs pre-loaded with identical and/or
different miRNAs, can interfere with miRNA-recognition and
binding to targeted mRNAs (Bartel, 2009; Filipowicz et al., 2008;
Kelly and Russell, 2009; Pasquinelli, 2012; Saetrom et al., 2007).
We speculate that insertion of the mir-9T sequence between
twomir-124aT sequences in vE1 did not give the expected increase
in virus suppression in vivo and in vitro due to adverse local RNA
conformational changes, which may cause steric hindrance of
RISC-binding to the target sequences. The absence of mutations
in the miRNA-target region of six out of 13 (46%) brain-derived
viruses from mice that succumbed to the vE1 infection supports
this notion, suggesting a limited involvement of miRNA-machinery
in the vE1 virus suppression compared to that of the vE2 virus.
Nevertheless, in the remaining seven out of 13 moribund mice
infected with vE1, severe neurological disease was associated with
emergence of escape mutants in the brains. Emerging TBEV/DEN4
mutant viruses escaped the miRNA-mediated suppression by
deleting all miRNA-targets located between the TBEV E and
DEN4 NS1 protein genes. These ﬁndings are in line with our
previous observations of virus escape via deletion of miRNA-target
sequences in the 30NCR during replication in the CNS (Heiss et al.,
2011, 2012).
Analysis of the sequences of escape vE2 and vE1 mutants
provides new insight into the structural requirements for the
stem-anchor (SA) domain of the envelope protein E, as in several
instances we observed the emergence of viruses containing
chimeric E protein with various combinations of TBEV and DEN4
SA domain sequences (escape viruses vE2-Δ447, vE1-Δ402 and
vE1-Δ411). Both stem (H1 and H2 helices) and transmembrane
anchor (TM1 and TM2 helices) regions are believed to be involved
and play an active role in the formation of the E protein trimer and
the fusion to endosomal membrane during virus entry into the cell
(Fritz et al., 2011; Pangerl et al., 2011; Stiasny et al., 2013). Fritz
et al. (2011) recently demonstrated that the TM1 and/or TM2
regions of the TBEV E protein can be substituted by the corre-
sponding sequences derived from a distantly related ﬂavivirus
(Japanese encephalitis virus), but this resulted in dramatic reduc-
tion of virus growth in mammalian cells. Here, we found that a
much larger C-terminal part of TBEV E protein in vE1-Δ411 and
vE2-Δ447 was replaced by the sequence derived from mosquito-
borne DEN4 virus without negative impact on virus growth. These
rearrangements in the SA region did not affect virus replication
since both viruses were able to grow in Vero cells to high titers
(107 PFU/ml), similar to that of TBEV/DEN4 virus (data not
shown). Another interesting observation derived from the analysis
of the escape mutants is related to requirements for size and
content of the SA domain inserted between two E/NS1 signalase
cleavage sites that can support correct polyprotein processing.
Sequence analysis of vE1-Δ270 indicates that this escape mutant
has lost the entire DEN4 stem region and contained only 55 amino
acid residues between two E/NS1 signalase cleavage sites corre-
sponding to the truncated DEN4 TM1 and intact TM2 region. Such
virus also initiated productive infection and replicated in Vero cells
suggesting that proper polyprotein processing occurred.
Multiple miRNA co-targeting of the viral genome within the
two distantly located regions (the ORF and 30NCR) completely
abolished the neurotropism of virulent TBEV/DEN4 virus in mice.
Importantly, insertion of multiple miRNA-targets in vE1/A3,
vE1/A5, vE2/A3, and vE2/A5 viruses did not affect their protective
efﬁcacy, since mice immunized with a single dose of any of these
viruses were completely protected against severe IP challenge
with neuroinvasive TBEV/LGT virus. Our studies in neonatal mice
demonstrated that extensive miRNA co-targeting of viral genomes
in the ORF and 30NCR had an additive effect and produced a more
potent attenuation of neurovirulence compared to separate target-
ing of those regions. No viral replication was detected in the
developing mouse brain after infection with viruses carrying six
targets for brain-expressed miRNAs. Furthermore, no viral anti-
gens were detected in neurons of mice intracerebrally inoculated
with such viruses, and the integrity of neuronal somatodendritic
compartments in the brain appeared well preserved.
In conclusion, we describe here an effective approach to
attenuate the pathogenicity of neurotropic viruses which prevents
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virus escape and reversion to a neurovirulent phenotype. TBEV/
DEN4 viruses with six copies of target sequences for brain-
expressed miRNA within the ORF and 30NCR were unable to
replicate in neurons in vivo; however, they induced a humoral
antibody response in immunized mice and provided protection
against subsequent challenge with neurovirulent virus. This
approach can be adapted for other viruses in order to minimize
their replication in a cell type speciﬁc manner, but most impor-
tantly, to prevent virus escape from miRNA-mediated silencing.
Materials and methods
Viruses
All miRNA-targeted viruses were derivatives of an infectious
cDNA clone of chimeric TBEV/DEN4 virus (GenBank access #
FJ28986) (Pletnev et al., 1992) generated using reverse genetics
technology. In the chimeric TBEV/DEN4 virus, the sequence
encoding the structural prM and E proteins of mosquito-borne
Dengue type 4 (DEN4) virus was replaced with the corresponding
region (nucleotides (nt) 415–2376) derived from the Far Eastern
TBEV strain Sofjin. Recombinant chimeric TBEV/LGT virus was
created by replacing the prM and E structural protein genes of the
highly attenuated E5 strain of tick-borne Langat virus (LGT)
(Pletnev, 2001) with the corresponding TBEV genes derived from
the TBEV/DEN4 chimera. (Construction of the TBEV/LGT will be
published elsewhere.) The TBEV/DEN4 cDNA contains aunique Xho
I site at nucleotide (nt) position 2364, at the junction between the
TBEV and DEN4 sequences in the E protein gene (Fig. 1A). Insertion
of the synthetic sequence E1 (Fig. S1 in the supplemental material)
(Blue Heron Biotechnology) at this site resulted in the TBEV/DEN4-
E1 virus (designated vE1) carrying three complementary miRNA
targets between the sequence encoding the TBEV envelope E
protein and the sequence encoding the DEN4 non-structural
protein NS1 (Fig. 1B). Speciﬁcally, the introduced E1 sequence
encoded 25 C-terminal amino acids of protein E and 10 N-terminal
amino acids of protein NS1 of TBEV, followed by three targets for
cellular miRNAs expressed in brain tissue (one target (T) for mir-9
and two Ts for mir-124a), and then by the sequence encoding 73
amino acids from the C-terminal end of the DEN4 E protein.
Recombinant cDNA genomes of TBEV/DEN4-E2 or TBEV/DEN4-E3
(designated vE2 or vE3, respectively) were generated by replace-
ment of the BsiWI-SﬁI fragment of vE1 cDNA with a 110 nt
synthetic E2 sequence containing three targets for mir-124a
miRNA, or with an E3 sequence containing scrambled target
sequences for mir-9 and mir-124a (Fig. S1). The vE1-FLAG cDNA
was generated by substitution of the XhoI-BsiWI DNA fragment in
the vE1 cDNA with a synthetic 139 nt fragment E-FLAG (Blue
Heron Biotechnology) (Fig. S1) containing 76 nts of the 30 end of a
TBEV protein E gene, 30 nts of the 50 end of NS1 coding sequence
and 24 nts encoding FLAG-tag (DYKDDDDK). The same strategy
was used to generate the vE2-FLAG and vE3-FLAG cDNAs. Two
miRNA-targeted viruses, TBEV/DEN4 3x mir124aT(1,2,4) [desig-
nated vA3] and TBEV/DEN4 3x mir124aT(1,2,5) [designated vA5],
were constructed previously (Heiss et al., 2012) and used in this
study to generate TBEV/DEN4 viruses for simultaneous multiple
targeting of the virus genome in the 30NCR and ORF between the
TBEV E and DEN4 NS1 genes. The DNA fragment from vA3 or vA5
cDNA that contained the 30NCR with inserted 3x mir-124a targets
at the sites 1,2,4 or sites 1,2,5 (Heiss et al., 2012) was used for
replacement of the corresponding sequence in the full-length
cDNA genomes of vE1, vE2, or vE3. Full-length cDNA of four newly
engineered viruses (designated vE1/A3, vE1/A5, vE2/A3, and vE2/A5)
carrying 6 miRNA targets and two viruses (vE3/A3 and vE3/A5)
carrying three miRNA-targets in the 30NCR and scrambled target
sequences between TBEV E and DEN4 NS1 protein genes were
constructed, as shown in Fig. 1C.
RNA transcripts generated from modiﬁed TBEV/DEN4 cDNAs
were used to transfect monolayers of Vero cells in the presence of
Lipofectamine as described previously (Engel et al., 2010;
Rumyantsev et al., 2006). All rescued viruses were biologically
cloned by two or three terminal dilutions and ampliﬁed in Vero
cells. Virus titers were determined in Vero cells by a plaque-
forming assay (PFA) as described previously (Rumyantsev et al.,
2006).
Immunoblot analysis
Vero cells in 6-well plates were infected with recombinant
viruses at an MOI of 0.5. At 72 h post-infection (p.i.), cell culture
supernatants were collected and clariﬁed by centrifugation at
16,000 g for 10 min at 4 1C to remove cell debris. Cells were
washed twice with phosphate buffer saline (PBS) and lysed in
buffer (25 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-
40, and 5% glycerol) supplemented with Halt™ Protease Inhibitor
Cocktail (Thermo Scientiﬁc). Lysates were collected and clariﬁed
by centrifugation at 16,000 g for 5 min at 4 1C. Cell culture
supernatants or cell lysates were mixed with the 4 protein
sample buffer (NuPAGE) supplemented with 10% β-mercaptoetha-
nol, and incubated for 5 min at 95 1C. Proteins were separated by
electrophoresis on 4–12% Bis-TrisNuPAGE gel (Invitrogen) with
morpholinee than sulfonic acid buffer (Invitrogen) and electro-
transferred onto polyvinylidene diﬂuoride membranes (Bio-Rad).
After blocking of the membranes with 3% blocking reagent (GE
Healthcare Life Sciences) in Tris-buffered saline–0.5% Tween 20
(TBS-T), they were incubated overnight at 4 1C with primary
antibodies: (TBEV- or DEN4-speciﬁc hyperimmune mouse ascitic
ﬂuid (HMAF) at a 1:1000 dilution, ATCC; mouse monoclonal anti-
DYKDDDDK Tag (anti-FLAG) antibody at a1:2000 dilution, Gen-
Script Inc.). Membranes were washed in TBS-T and then incubated
for 1 h at room temperature in the presence of secondary horse-
radish peroxidase-conjugated antibodies (GE Healthcare Life
Sciences). Membranes were developed with the ECL™-Prime
Western detection reagent (GE Healthcare Life Sciences) and
bands were visualized on Kodak BiomaxMR ﬁlm.
Kinetics of virus growth in primary neuronal cells
Primary rat neurons (Gibco) were grown in BD BioCoat 8-well
glass slides (BD Biosciences) (105 cells/chamber) for 8 days accord-
ing to the manufacturer’s protocol and then infected with viruses
at an MOI of 0.1. Cell supernatants were collected at days 3 and 4 p.
i. and virus titers were determined in Vero cells. Viral RNA was
extracted from cell supernatants and used for sequence analysis.
Virus-infected cells on glass slides were ﬁxed with 4% paraformal-
dehyde and processed for detection of viral antigens as described
previously (Heiss et al., 2011).
Evaluation of viruses in mice
Studies in mice were performed at the Animal BSL-3 facilities,
in compliance with the guidelines of the NIAID Institutional
Animal Care and Use Committee, as described previously (Heiss
et al., 2012). Brieﬂy, for virus neurovirulence evaluation, litters of
9 or 10 3-day-old Swiss Webster mice (Taconic Farms) were
inoculated intracerebrally (IC) with 10, 102, or 103 PFU of corre-
sponding virus and monitored for morbidity and mortality up to
21 days p.i. The LD50 was determined by the Reed and Muench
method (Reed and Muench, 1938). Moribund (paralyzed) mice
were euthanized and their brain homogenates were prepared as
described previously (Engel et al., 2010; Pletnev et al., 2006). Viral
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RNA was extracted from brain homogenates, and the sequence of
the genomic region containing engineered miRNA-targets was
determined. On day 22 p.i. surviving mice were euthanized and
their brains were collected. Virus presence in brain homogenates
was evaluated by direct titration and after one blind passage in
Vero cells.
To analyze virus replication and distribution of viral antigens in
the brain, as well as to evaluate the extent of virus-induced
neuronal damage, 3-day-old mice were inoculated IC with
103 PFU of the vE1/A3, vE1/A5, vE2/A3, vE2/A5, or vE3/A5 virus.
Control mice were mock-inoculated with Leibovitz’s L-15 medium
(Invitrogen). For analysis of virus replication, the brains of three
mice from each group were collected on days 8, 13, and 20 p.i.
Virus titers in brain suspensions were quantitated by titration in
Vero cells. Virus RNA was extracted from brain homogenates and
used for RT-PCR and sequence analyses. For the analysis of viral
antigens and neuronal damage, the brains of three mice from each
group were collected on days 13 and 20 p.i. In addition, the brains
of three mice inoculated IC with 103 PFU of the parental TBEV/
DEN4 were collected when the mice became moribund (day 6 p.i.)
to serve as a positive control. All brains were histologically
processed using MultiBrain Technology (NeuroScience Associates)
and analyzed by immunohistochemistry for presence of TBEV
antigens, microglial activation, and integrity of neuronal somato-
dendritic compartments as previously described (Heiss et al.,
2012).
Immunogenicity and protective efﬁcacy of miRNA-target
viruses were assessed in 3-week-old Swiss Webster female mice.
Mice were inoculated intraperitoneally (IP) with 105 PFU of each
virus, and sera were collected on day 28 p.i. to evaluate neutraliz-
ing antibody response. TBEV-speciﬁc neutralizing antibody titers
were determined by the 60% plaque reduction neutralization assay
(PRNT60%) in Vero cells as previously described (Pletnev et al.,
2001; Rumyantsev et al., 2006). The neutralizing antibody titer
was deﬁned as the dilution of serum that neutralized 60% of the
TBEV/DEN4 virus used in the assay. Mice were challenged IP on
day 29 with 100 IP LD50 (3200 PFU) of the neuroinvasive TBEV/LGT
virus, and observed for morbidity and mortality for an additional
4 weeks.
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